Rachel Graves

Rachel Graves currently serves as Senior Director of CMC at Longboard Pharmaceuticals, a position held since January 2022, following a tenure as Director of CMC. Prior to this role, Rachel Graves was Director of CMC Development and Associate Director of Analytical R&D at Esperion from 2020 to January 2022. Rachel Graves spent over a decade at GSK from 2007 to 2019, progressing from Investigator/Principal Scientist to Scientific Manager/Team Leader, where significant contributions were made as CMC Analytical Lead and Physical Properties Project Lead. Educational background includes a Bachelor of Science in Chemical Engineering from Bucknell University and a Ph.D. in Pharmaceutical Sciences from the University of the Sciences in Philadelphia.